Evidence map›Paper›PMID 30784225›Full record

ArticleStem cells translational medicine2019

Bone Morphogenetic Protein-6 Attenuates Type 1 Diabetes Mellitus-Associated Bone Loss.

Jesse F Wang, Ming-Song Lee, Tsung-Lin Tsai, Ellen M Leiferman, Darrin J Trask, Matthew W Squire, Wan-Ju Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jesse F WangDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ming-Song LeeDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Tsung-Lin TsaiDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Ellen M LeifermanDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Darrin J TraskDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Matthew W SquireDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Wan-Ju LiDepartment of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-6579-8063
University of Wisconsin–Madison · USUW Health University Hospital · US

Funding

Blood-derived Induced Pluripotent Stem Cells for Cartilage RepairR01AR064803 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI LI, WAN-JU · 2015 to 2019
$1.6M
NIAMS NIH HHS R01 AR064803
6 · The paper itself

Abstract

Patients with type 1 diabetes mellitus (T1DM) often suffer from osteopenia or osteoporosis. Although most agree that T1DM-induced hyperglycemia is a risk factor for progressive bone loss, the mechanisms for the link between T1DM and bone loss still remain elusive. In this study, we found that bone marrow-derived mesenchymal stem cells (BMSCs) isolated from T1DM donors were less inducible for osteogenesis than those from non-T1DM donors and further identified a mechanism involving bone morphogenetic protein-6 (BMP6) that was produced significantly less in BMSCs derived from T1DM donors than that in control cells. With addition of exogenous BMP6 in culture, osteogenesis of BMSCs from T1DM donors was restored whereas the treatment of BMP6 seemed not to affect non-T1DM control cells. We also demonstrated that bone mineral density (BMD) was reduced in streptozotocin-induced diabetic mice compared with that in control animals, and intraperitoneal injection of BMP6 mitigated bone loss and increased BMD in diabetic mice. Our results suggest that bone formation in T1DM patients is impaired by reduction of endogenous BMP6, and supplementation of BMP6 enhances osteogenesis of BMSCs to restore BMD in a mouse model of T1DM, which provides insight into the development of clinical treatments for T1DM-assocaited bone loss. Stem Cells Translational Medicine 2019;8:522-534.

Indexed as

AnimalsBone and BonesBone DensityBone Diseases, MetabolicBone Morphogenetic Protein 6Bone Morphogenetic Protein Receptors, Type IICell DifferentiationDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, Inbred C57BLOsteogenesisReceptor, Transforming Growth Factor-beta Type IIRecombinant ProteinsBone Morphogenetic Protein 6Bone Morphogenetic Protein Receptors, Type IIReceptor, Transforming Growth Factor-beta Type IIRecombinant ProteinsBone lossBone morphogenetic protein-6HyperglycemiaMesenchymal stem cellOsteogenesisType 1 diabetes mellitus

Identifiers

PMID30784225
PMCPMC6525561
OpenAlexW2915933075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.